The global GLP-1 receptor agonist market is poised for remarkable expansion in the coming decade, according to a recent market analysis. Projections suggest an impressive surge from US$ 23,854.53 ...

The researchers treated cancer cells with a combination of venetoclax, a current standard-of-care drug for AML, and a STING ...

Palatin Technologies (PTN) stock gains as the FDA clears a study to test its obesity therapy bremelanotide, with Eli Lillys ...

With the FDA greenlighting its investigational new drug (IND) application, the company is eyeing a mid-2024 timeline to begin ...

With its newly launched predictive analytics platform, Real Chemistry is hoping to “shine a light” on the GLP-1 agonist ...

"The conclusion of enrollment for Regimen G marks a critical step forward for the HEALEY ALS platform Trial," said Drs. Paganoni and Babu. "We extend our thanks to Denali, academic collaborators, and ...

A first-in-class interleukin (IL)-15 receptor agonist, the drug is specifically approved in combination with BCG for adults ...

DD01 is a long-acting dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptors. The designation was based on data from a randomized, double-blind, placebo-controlled phase 1 study ...

Glucagon-like peptide 1 (GLP1) receptor agonist use does not appear to be associated with an increased risk for thyroid ...

In the majority of IVF cycles, whether using an agonist or an antagonist protocol, the trigger used is human chorionic gonadotropin (hCG), which shares a common subunit with LH and thus acts as a ...

The primary endpoints in Type 2 diabetes and obesity GLP-1 receptor agonist trials are usually glycated haemoglobin (HbA1c) ...